Tim Dyer
Founder bei ADDEX THERAPEUTICS LTD
Vermögen: 2 Mio $ am 31.03.2024
Ursprung des Netzwerks ersten Grades von Tim Dyer
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 27 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Tim Dyer
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chairman | |
| NEKTAR THERAPEUTICS | Pharmaceuticals: Major | Chairman Chief Operating Officer | |
| VERNALIS | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Miscellaneous Commercial Services | Director/Board Member | |
Calibra Medical LLC
 Calibra Medical LLC Medical SpecialtiesHealth Technology Calibra Medical LLC develops and markets medical devices and technologies in the diabetes sector. Its products include finesse and insulin delivery devices. The company was founded by Daniel Hawkins and Clifton A. Alferness in 2004 and is headquartered in Wayne, PA. | Medical Specialties | Director/Board Member | |
GlaxoSmithKline KK
 GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables GlaxoSmithKline KK researches, develops, imports, manufactures and sells toiletry products. The company was founded on August 18, 1928 and is headquartered in Tokyo, Japan | Household/Personal Care | Corporate Officer/Principal | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree | |
| ACTELION | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member | |
| École Polytechnique Fédérale de Lausanne | College/University | Graduate Degree | |
| University of Cambridge | College/University | Doctorate Degree Corporate Officer/Principal | |
Basel - SpA
 Basel - SpA MiscellaneousMiscellaneous Part of Smith & Nephew plc, Basel SpA is an Italian company that specializes in medicinal chemicals and botanical products. The private company is based in Ravenna, Italy. Basel was acquired by Smith & Nephew plc on April 01, 1995 for $4.80 million. | Miscellaneous | Corporate Officer/Principal | |
| OREXO AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Axovan AG
 Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| BASILEA PHARMACEUTICA AG | Pharmaceuticals: Major | Chairman | |
| University of London | College/University | Doctorate Degree Doctorate Degree | |
| University of Vermont | College/University | Doctorate Degree | |
deVGen NV
 deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Biotechnology | Corporate Officer/Principal | |
| University of Geneva | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member Chairman | |
| University of Paris Jussieu | College/University | Doctorate Degree | |
Merck Serono SA
 Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
Roche Ltd.
 Roche Ltd. Financial ConglomeratesFinance Roche Ltd. provides investment services. | Financial Conglomerates | Corporate Officer/Principal | |
| University of Lyon | College/University | Doctorate Degree | |
| DIMERIX LIMITED | Pharmaceuticals: Major | Director/Board Member | |
GlaxoSmithKline AG
 GlaxoSmithKline AG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AG is a Swiss company. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Urrma AG
 Urrma AG Pharmaceuticals: MajorHealth Technology Urrma AG is a Swiss pharmaceutical company that focuses on research and development, manufacturing, and marketing of pharmaceutical products. The private company is based in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Biogen International GmbH
 Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Synchronicity Pharma, Inc.
 Synchronicity Pharma, Inc. Pharmaceuticals: OtherHealth Technology Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA. | Pharmaceuticals: Other | Director/Board Member | |
| TET Systems AG | Director/Board Member | ||
| Pivalor AG | Chief Executive Officer | ||
Resurge International
 Resurge International Medical/Nursing ServicesHealth Services Resurge International operates surgical care facilities for poor children and adults. | Medical/Nursing Services | Director/Board Member | |
| 4D MOLECULAR THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| CYTOMX THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman | |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
| PLIANT THERAPEUTICS, INC. | Biotechnology | Chairman | |
Quintessa Investment Co. Ltd.
 Quintessa Investment Co. Ltd. Investment ManagersFinance Quintessa Investment acts as alternative investment manager. It is engaged in financial investment activities. The company was founded on January 13, 2011 and is headquartered in Seoul, South Korea. | Investment Managers | Private Equity Investor | |
pH Pharma Co., Ltd.
 pH Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology pH Pharma Co. Ltd. engages in the developing and manufacturing of bio-pharmaceuticals. Its products include php-303, php-201, ab-101, nuvesse, alpine and torpedo products. The company was founded by Ho Young Huh on September 22, 2015 and is headquartered in Seoul, South Korea. | Pharmaceuticals: Major | Chief Executive Officer | |
| EIDOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| Healthcare & Humanity Foundation | Founder | ||
Peak Bio Co. Ltd.
 Peak Bio Co. Ltd. BiotechnologyHealth Technology Part of Peak Bio, Inc., Peak Bio Co. Ltd. is a South Korean clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and inflammation. Peak Bio's location is in Seongnam, South Korea. The private company's lead product candidate, php-303, is a small molecule currently in phase II clinical study for the orphan disease alpha1 anti-trypsin deficiency. Peak Bio has successfully completed phase I trials, demonstrating dose-dependent pharmacokinetics and establishing a dose for upcoming clinical trials. The company's cancer platform includes novel payloads and antibody-drug-conjugates (ADC) to address unmet needs in cancer care. The company was founded in 2015, and the CEO is Ho Young Huh. Peak Bio Co. was acquired by Ignyte Acquisition Corp. on November 01, 2022 for $353.84 million. | Biotechnology | Chief Executive Officer | |
| PEAK BIO, INC. | Pharmaceuticals: Major | Chairman | |
MedXCell SA
 MedXCell SA BiotechnologyHealth Technology MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then. | Biotechnology | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 20 |
| Schweiz | 16 |
| Vereinigtes Königreich | 5 |
| Frankreich | 4 |
| Südkorea | 4 |
Sektoral
| Health Technology | 32 |
| Consumer Services | 9 |
| Finance | 4 |
| Commercial Services | 3 |
| Consumer Non-Durables | 2 |
Operativ
| Director/Board Member | 172 |
| Corporate Officer/Principal | 71 |
| Independent Dir/Board Member | 31 |
| Chairman | 28 |
| Chief Executive Officer | 18 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Antoine Papiernik | 48 |
| Ho Young Huh | 32 |
| Bharatt Chowrira | 24 |
| Beat E. Lüthi | 23 |
| Jake Nunn | 23 |
| Graham Dixon | 18 |
| Ray Hill | 18 |
| Isaac Manke | 15 |
| Oleg Nodelman | 15 |
| Alexandra Goll | 14 |
| Vincent Lawton | 12 |
| Werner Henrich | 10 |
| André J. Müller | 10 |
| Roger G. Mills | 8 |
| Vincent Mutel | 8 |
